𝛼SK or Searchbearish
Samsung Biologics - Impact of 3 Trillion Won in Rights Offering Capital Raise
124 Views28 Aug 2026 17:57
On 28 August, Samsung Biologics (207940 KS) announced a rights offering capital raise worth nearly 3 trillion won, mainly to fund the acquisition of the Swiss CDMO firm PolyPeptide.
What is covered in the Full Insight:
- Introduction to Samsung Biologics Rights Offering
- Details of the Rights Offering
- Implications for Samsung Biologics' Share Price
- PolyPeptide Acquisition Rationale
- Future Investment and Growth Prospects
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Samsung Biologics - Impact of 3 Trillion Won in Rights Offering Capital Raise28 Aug 2026
- Samsung Bioepis Holdings and Samsung Biologics to Start Trading on 24 November20 Nov 2025
- Samsung Biologics: Creation of a Holding Company to Split CDMO and Biosimilar Businesses22 May 2025
- Samsung Biologics: Rights Offering of 3 Trillion Won to Acquire Remaining Stake in Samsung Bioepsis01 Feb 2022
x